Skip to main content

Advertisement

SpringerLink
Log in

Saccharomyces boulardii in childhood

  • Review
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

An Erratum to this article was published on 24 February 2009

Abstract

Introduction

Probiotics are live microorganisms which confer a health benefit on the host. Saccharomyces boulardii, a yeast, has been found to be an effective probiotic in double-blind placebo-controlled randomized clinical studies.

Materials and methods

We reviewed the established mechanisms of actions and clinical efficacy in children of S. boulardii.

Conclusions

The mechanisms of action of S. boulardii depend mainly on the inhibition of some bacterial toxins, anti-inflammatory effects, and on stimulating effects on the intestinal mucosa such as trophic effects on the brush border enzymes and immunostimulatory effects. At present, in pediatric populations, there is evidence that S. boulardii is beneficial for the treatment of acute gastroenteritis and the prevention of antibiotic-associated diarrhea. More data are needed in other indications such as traveller’s diarrhea, Helicobacter pylori eradication, and inflammatory bowel disease. S. boulardii is a yeast strain that has been extensively studied in vitro and in vivo. Recent data have opened the door for new therapeutic indications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Andersson H, Asp NG, Bruce A et al (2001) Health effects of probiotics and prebiotics. A literature review on human studies. Scand J Nutr 45:58–95

    Google Scholar 

  2. Barbut F, Meynard JL, Guiguet M et al (1997) Clostridium difficile-associated diarrhea in HIV infected patients: epidemiology and risk factors. J Acq Immun Def Synd 16:176–181

    CAS  Google Scholar 

  3. Bartlett JG, Chang TW, Gurwith M et al (1978) Antibiotic-associated pseudomembranous colitis due to toxin producing Clostridia. N Engl J Med 298:531–534

    PubMed  CAS  Google Scholar 

  4. Bartlett JG (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346:334–339

    Article  PubMed  Google Scholar 

  5. Bassetti S, Frei R, Zimmerli W (1998) Fungemia with Saccharomyces cerevisiae after treatment with S. boulardii. Am J Med 105:71–72

    Article  PubMed  CAS  Google Scholar 

  6. Baumgart D (2007) The probiotic yeast Saccharomyces boulardii inhibits DC-induced activation of naïve T-cells. Gastroenterology 135(4):A–559 (sup 1)

    Google Scholar 

  7. Benhamou PH, Berlier P, Danjou G et al (1999) Antibiotic-associated diarrhoea in children: a computer monitored double-blind outpatients trial comparing a protective and a probiotic agent. Med Chir Dig 28:163–168

    Google Scholar 

  8. Bernet MF, Brassart D, Neeser JR et al (1994) Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 35:483–489

    Article  PubMed  CAS  Google Scholar 

  9. Bhatia SJ, Kochar N, Abraham P et al (1989) Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol 27:2328–2330

    PubMed  CAS  Google Scholar 

  10. Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Saeed Shekhani M, Siddiqi AQ (2006) Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 12:4557–4560

    PubMed  CAS  Google Scholar 

  11. Bléhaut H, Massot J, Elmer GW et al (1989) Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 10:353–364

    Article  PubMed  Google Scholar 

  12. Breves G, Faul K, Schröder B et al (2000) Application of the colon-stimulation technique for studying the effects of Saccharomyes boulardii on basic parameters of porcine cecal microbial metabolism disturbed by Clindamycin. Digestion 61:193–200

    Article  PubMed  CAS  Google Scholar 

  13. Brunser O (2009) Coincubation of Saccharomyces boulardii with Helicobacter pylori. A Morphological Study (in press)

  14. Burkhardt O, Köhnlein T, Pletz M et al (2005) Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis 37:69–72

    Article  PubMed  CAS  Google Scholar 

  15. Buts JP, Bernasconi P, Vaerman JP et al (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35:251–256

    Article  PubMed  CAS  Google Scholar 

  16. Buts JP, Bernasconi P, Van Craynest MP et al (1986) Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20:192–196

    Article  PubMed  CAS  Google Scholar 

  17. Buts JP, Corthier G, Delmee M (1993) Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 16:419–425

    PubMed  CAS  Google Scholar 

  18. Buts JP, De Keyser N, De Raedemaeker L (1994) Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 36:522–527

    Article  PubMed  CAS  Google Scholar 

  19. Buts JP, Duranton B, De Keyser N et al (1998) Premature stimulation of rat sucrase-isomaltase (SI) by exogenous insulin and the analog B-Asp10 is regulated by a receptor-mediated signal triggering SI gene transcription. Pediatr Res 43:585–591

    Article  PubMed  CAS  Google Scholar 

  20. Buts JP, De Keyser N, Marandi S et al (1999) Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut 45:89–96

    PubMed  CAS  Google Scholar 

  21. Buts JP, De Keyser N, Stilmant C et al (2002) Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc-binding metalloprotease. Pediatr Res 51:528–534

    Article  PubMed  CAS  Google Scholar 

  22. Buts JP, Dekeyser N, Stilmant C et al (2006) Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res 60:24–29

    Article  PubMed  CAS  Google Scholar 

  23. Canani RB, Cirillo P, Terrin GA et al (2007) Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 335:340–347

    Article  PubMed  Google Scholar 

  24. Castagliuolo I, LaMont JT, Nikulasson ST et al (1996) Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 12:5225–5232

    Google Scholar 

  25. Castagliuolo I, Riegler MF, Valenick L et al (1999) Saccharomyces boulardii protease mediates Clostridium difficile toxin A and B effects in human colonic mucosa. Infect Immun 67:302–307

    PubMed  CAS  Google Scholar 

  26. Castaneda C, Garcia E, Santa Cruz M, Fernandez M, Monterrey P (1995) Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Rev Mex Pueric Pediatr 2:12–16

    Google Scholar 

  27. Cetina-Sauri G, Busto GS (1994) Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Ann Ped 6:397–400

    Google Scholar 

  28. Cindoruk M, Erkan G, Karakan T et al (2007) Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 12:309–316

    Article  PubMed  Google Scholar 

  29. Czerucka D, Dahan S, Mograbi B et al (2000) Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 68:5998–6004

    Article  PubMed  CAS  Google Scholar 

  30. Czerucka D, Piche T, Rampal P (2007) Review article: yeast as probiotics—Saccharomyces boulardii. Aliment Pharmacol Ther 26:767–778

    PubMed  CAS  Google Scholar 

  31. Czerucka D, Rampal P (2002) Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4:733–739

    Article  PubMed  Google Scholar 

  32. Czerucka D, Roux I, Rampal P (1994) Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′, 5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106:65–72

    PubMed  CAS  Google Scholar 

  33. Dahan S, Dalmasso G, Imbert V et al (2003) Saccharomyces boulardii interfers with enterohemorragic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71:766–773

    Article  PubMed  CAS  Google Scholar 

  34. Dalmasso G, Cottrez F, Imbert V et al (2006) Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131:1812–1825

    Article  PubMed  CAS  Google Scholar 

  35. Dalmasso G, Loubat A, Dahan S et al (2006) Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells. Res Microbiol 157:456–465

    Article  PubMed  CAS  Google Scholar 

  36. de Llanos R, Querol A, Pemán J et al (2006) Food and probiotic strains from the Saccharomyces cerevisiae species as a possible origin of human systemic infections. Int J Food Microbiol 110:286–289

    Article  PubMed  CAS  Google Scholar 

  37. Desreumeaux P, Rousseaux C (2006) Influence of the intestinal microflora on host immunity in inflammatory bowel disease. In G. Microflora Ed. John Libbey Eurotext

  38. Duman DG, Bor S, Ozütemiz O et al (2005) Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 17:1357–1361

    Article  PubMed  Google Scholar 

  39. Elmer GW, Corthier G (1991) Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol 37:315–317

    PubMed  CAS  Google Scholar 

  40. Elmer GW, McFarland LV, Surawicz CM et al (1999) Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 13:1663–1668

    Article  PubMed  CAS  Google Scholar 

  41. Elmer GW, Moyer KA, Vega R et al (1995) Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microecol and Ther 25:23–31

    Google Scholar 

  42. Elstner CL, Lindsay AN, Book LS et al (1983) Lack of relationship of Clostridium difficile to antibiotic-associated diarrhea in children. Pediatr Inf Dis 2:364–366

    CAS  Google Scholar 

  43. Erdeve O, Tiras U, Dallar Y (2004) The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 50:234–236

    Article  PubMed  Google Scholar 

  44. FAO/WHO (2006) Probiotics in Food. Health and nutritional properties and guidelines for evaluation. FAO Food and Nutrition Paper 85 (ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf)

  45. Fietto JLR, Araújo RS, Valadão FN et al (2004) Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can J Microbiol 50:615–621

    Article  PubMed  CAS  Google Scholar 

  46. Gaon D, Garcia H, Winter L et al (2003) Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires) 63:293–298

    Google Scholar 

  47. Gedek BR (1999) Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42:261–264

    Article  PubMed  CAS  Google Scholar 

  48. Geyik MF, Aldemir M, Hosoglu S et al (2006) The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. Ann R Coll Surg Engl 88:176–180

    Article  PubMed  Google Scholar 

  49. Girard P, Pansart Y, Lorette I et al (2003) Dose–response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats. Dig Dis Sci 48:770–774

    Article  PubMed  CAS  Google Scholar 

  50. Goldman CG, Barrado DA, Balcarce N et al (2006) Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition 22:984–988

    Article  PubMed  Google Scholar 

  51. Gotteland M, Poliak L, Cruchet S et al (2005) Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr 94:1747–1751

    Article  PubMed  Google Scholar 

  52. Graf C, Gavazzi G (2007) Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. J Infect 54:310–311

    Article  PubMed  CAS  Google Scholar 

  53. Guarino A, Albano F, Ashkenazi S et al (2008) The ESPGHAN/ESPID Guidelines for the Management of Acute Gastroenteritis in Children in Europe. J Pediatr Gastroenterol Nutr 46:S81–S122

    Article  PubMed  Google Scholar 

  54. Hafeez A, Tariq P, Ali S et al (2002) The efficacy of Saccharomyces boulardii in the treatment of acute watery diarrhea in children: a multicentre randomized controlled trial. J Coll Phys Surg Pakist 12:432–434

    Google Scholar 

  55. Hennequin C, Kauffman-Lacroix C, Jobert A et al (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Diseases 19:16–20

    Article  CAS  Google Scholar 

  56. Hennequin C, Thierry A, Richard GF et al (2001) Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 39:551–559

    Article  PubMed  CAS  Google Scholar 

  57. Herek O, Kara IG, Kaleli I (2004) Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury. Surg Today 34:256–260

    Article  PubMed  CAS  Google Scholar 

  58. Htwe K, Yee KS, Tin M, Vandenplas Y (2008) Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg 78:214–216

    PubMed  Google Scholar 

  59. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216

    Article  PubMed  CAS  Google Scholar 

  60. Jawhara S, Poulain D (2007) Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol 45:691–700

    Article  PubMed  CAS  Google Scholar 

  61. Klein SM, Elmer GW, McFarland LV et al (1993) Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 10:1615–1619

    Article  PubMed  CAS  Google Scholar 

  62. Kotowska M, Albrecht P, Szajewska H (2005) Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 21:583–590

    Article  PubMed  CAS  Google Scholar 

  63. Kurugol Z, Koturoglu G (2005) Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 94:44–47

    Article  PubMed  CAS  Google Scholar 

  64. Lionetti E, Miniello VL, Castellaneta SP et al (2006) Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 24:1461–1468

    Article  PubMed  CAS  Google Scholar 

  65. Luyer MD, Buurman WA, Hadfoune M et al (2005) Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun 73:3686–3692

    Article  PubMed  CAS  Google Scholar 

  66. Mathur S, Singh R (2005) Antibiotic resistance in food lactic acid bacteria—a review. Int J Food Microbiol 105:281–295

    Article  PubMed  CAS  Google Scholar 

  67. McFarland LV, Surawicz CM, Stamm WE (1990) Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 162:678–684

    PubMed  CAS  Google Scholar 

  68. McFarland LV (1998) Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 16:292–307

    Article  PubMed  CAS  Google Scholar 

  69. Mumy KL, Chen X, Kelly CP et al (2008) Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 294:G599–G609

    Article  PubMed  CAS  Google Scholar 

  70. Muñoz P, Bouza E, Cuenca-Estrella M et al (2005) Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 40:1625–1634

    Article  PubMed  Google Scholar 

  71. Piechno S, Seguin P, Gangneux JP (2007) Saccharomyces boulardii fungal sepsis: beware of the yeast. Can J Anaesth 54:245–246

    Article  PubMed  Google Scholar 

  72. Pothoulakis C, Kelly CP, Joshi MA et al (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104:1108–1115

    PubMed  CAS  Google Scholar 

  73. Riedel BD, Ghishan FK (1996) Acute diarrhea. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB (eds) Pediatric gastrointestinal disease, 2nd edn. Mosby-Year Book Inc., St. Louis, pp 251–262

    Google Scholar 

  74. Rigothier MC, Maccario J, Vuong PN et al (1990) Effects of Saccharomyces boulardii yeast on trophozoites of Entamoeba histolytica in vitro and in cecal amebiasis in young rats. Ann Parasitol Hum Comp 65:51–60

    PubMed  CAS  Google Scholar 

  75. Rijnders BJA, Van Wijngaerden E, Verwaest C et al (2000) Saccharomyces fungemia complicating S. boulardii treatment in a non-immunocompromised host. Intensive Care Med 26:825

    Article  PubMed  CAS  Google Scholar 

  76. Rodrigues ACP, Nardi RM, Bambirra EA et al (1996) Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri conventional and gnotobiotic mice. J Appl Bacteriol 91:251–256

    Google Scholar 

  77. Schneider SM, Girard-Pipau F, Filippi J et al (2005) Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 11:6165–6169

    PubMed  CAS  Google Scholar 

  78. Sougioultzis S, Simeonidis S, Bhaskar KR et al (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343:69–76

    Article  PubMed  CAS  Google Scholar 

  79. Sykora J, Valeckova K, Amlerova J et al (2005) Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol 39:692–698

    Article  PubMed  CAS  Google Scholar 

  80. Szajewska H, Setty M, Mrukowicz J et al (2006) Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 42:454–475

    Article  PubMed  Google Scholar 

  81. Szajewska H, Skórka A, Dylag M (2007) Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 25:257–264

    PubMed  CAS  Google Scholar 

  82. Temmerman R, Pot B, Huys G et al (2003) Identification and antibiotic susceptibility of bacterial isolates from probiotic products. Int J Food Microbiol 81:1–10

    Article  PubMed  CAS  Google Scholar 

  83. Tong JL, Ran ZH, Shen J et al (2007) Meta-analysis: the effect of supplementation with probiotics on eradication rates and side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 25:155–168

    Article  PubMed  CAS  Google Scholar 

  84. Turck D, Bernet JP, Marx J et al (2003) Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 37:22–26

    Article  PubMed  CAS  Google Scholar 

  85. Vandenplas Y, Salvatore S, Vieira M et al (2007) Probiotics in infectious diarrhoea in children: are they indicated? Eur J Pediatr 166:1211–1218

    Article  PubMed  CAS  Google Scholar 

  86. Villarruel G, Rubio DM, Lopez F et al (2007) Saccharomyces boulardii in acute childhood diarrhea: a randomized controlled study. Acta Paediatr 96:538–541

    Article  PubMed  Google Scholar 

  87. WHO (2003) The treatment of diarrhoea. A manual for physicians and other senior health workers. WHO/CAH/03.7 10/03

  88. WHO (1995) The treatment of diarrhea. A manual for physicians and other senior health workers; WHO/CDR/95.3. Geneva, World Health Organization

  89. Wiström J, Norrby SR, Myhre EB et al (2001) Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 47:43–50

    Article  PubMed  Google Scholar 

  90. Wu X, Vallance BA, Boyer L et al (2008) Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol 294:G295–G306

    Article  PubMed  CAS  Google Scholar 

  91. Zunic P, Lacotte J, Pegoix M et al (1991) S. boulardii fungemia. Apropos of a case. Therapie 46:498–499

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitair Ziekenhuis Kinderen Brussel, Vrije Universiteit Brussel, Laarbeekl 101, 1090, Brussels, Belgium

    Yvan Vandenplas

  2. Institute of Nutrition and Food Technology (INTA), U. of Chile, Santiago, Chile

    Oscar Brunser

  3. The Medical University of Warsaw, Warsaw, Poland

    Hania Szajewska

Authors
  1. Yvan Vandenplas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oscar Brunser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hania Szajewska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yvan Vandenplas.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00431-009-0947-7

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vandenplas, Y., Brunser, O. & Szajewska, H. Saccharomyces boulardii in childhood. Eur J Pediatr 168, 253–265 (2009). https://doi.org/10.1007/s00431-008-0879-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-008-0879-7

Keywords

Search

Navigation